arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Amneal Pharmaceuticals, Inc.

AMRX
$19.34 ▼ -0.15 (-0.77%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
51
Health
Fair
Neutral
auto_awesome

Analytical Summary

Amneal Pharmaceuticals, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $6.2B
Dividend Yield
Revenue Growth 9.9%
Op. Margin 16.3%
ROIC 4.9%
FCF / Share $-0.16
Trailing P/E 107.4x
Price / Book 186.9x
FCF Yield
Debt / Equity 77.83
info Valuation on last close. End-of-day price, Sep 23, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$796.20M
↑ +9.9%
Net Income Profit after all expenses
$57.66M
↑ +157.2%
Operating Margin Operating profit as % of sales
16.3%
↓ -16.9% 63th
FCF / Share Free cash flow per share
$-0.16
↓ -47.3%
Long-Term Debt Long-term obligations
$2.57B
— -0.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
54
Returns
8
Financial Health
80
Cash Quality
93

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 39 quarters